ArticleFrontiers in surgery2025
Meta-analysis of risk factors for recurrence in cervical cancer patients following fertility-sparing treatment.
Article in Frontiers in surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: To identify and evaluate the main risk factors for recurrence in cervical cancer patients who undergo fertility- sparing treatment. Methods: A comprehensive search of multiple databases, including PubMed, Embase, and Web of Science, was performed to identify studies assessing the recurrence risk in cervical cancer patients treated with fertility-sparing procedures. Data from eligible studies were pooled, and the relative risks (RR) with 95% confidence intervals (CI) were calculated to evaluate the association between various risk factors and recurrence risk. Results: Ten studies met inclusion criteria. Recurrence risk was significantly higher in patients aged ≤30 years (RR: 2.03, 95% CI: 1.89-2.19), those with tumor size ≥2 cm (RR: 1.94, 95% CI: 1.82-2.06), stage > IA within the fertility-sparing spectrum (RR: 2.46, 95% CI: 2.29-2.64), lymphovascular space invasion (LVSI) positivity (RR: 2.09, 95% CI: 1.90-2.30), and lymph-node metastasis (RR 3.10, 95% CI 2.76-3.48). Heterogeneity was low across comparisons Conclusion: Age ≤30 years, tumor size ≥2 cm, stage > IA, LVSI positivity, and lymph-node metastasis are robust predictors of recurrence following fertility-sparing treatment in cervical cancer. Incorporating these variables into preoperative counseling, operative strategy, and follow-up planning may enhance oncologic safety while preserving reproductive potential in appropriately selected patients. Our findings are consistent with current guideline recommendations, which generally limit fertility-sparing approaches to tumors ≤2 cm, while tumors exceeding this threshold require cautious consideration and are usually not regarded as appropriate candidates outside of clinical trials or exceptional multidisciplinary contexts.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.